24-Apr-2024
No headlines found.
Globe Newswire (Mon, 15-Apr 10:56 AM ET)
Business Wire (Mon, 15-Apr 7:00 AM ET)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire (Fri, 5-Apr 4:00 PM ET)
Business Wire (Wed, 27-Mar 8:41 AM ET)
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Business Wire (Tue, 19-Mar 4:15 PM ET)
Business Wire (Tue, 5-Mar 4:01 PM ET)
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire (Wed, 21-Feb 7:00 AM ET)
Business Wire (Tue, 20-Feb 7:00 AM ET)
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Marinus Pharmaceuticals trades on the NASDAQ stock market under the symbol MRNS.
As of April 24, 2024, MRNS stock price was flat at $1.44 with 1,303,219 million shares trading.
MRNS has a beta of 4.41, meaning it tends to be more sensitive to market movements. MRNS has a correlation of 0.08 to the broad based SPY ETF.
MRNS has a market cap of $79.10 million. This is considered a Micro Cap stock.
Last quarter Marinus Pharmaceuticals reported $7 million in Revenue and -$.74 earnings per share. This fell short of revenue expectation by $-820,000 and missed earnings estimates by -$.12.
In the last 3 years, MRNS stock traded as high as $19.83 and as low as $1.11.
The top ETF exchange traded funds that MRNS belongs to (by Net Assets): VTI, VXF, IWM, VTWO, IWO.
MRNS has underperformed the market in the last year with a price return of -82.2% while the SPY ETF gained +24.2%. MRNS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -85.5% and -82.8%, respectively, while the SPY returned +4.6% and -2.7%, respectively.
MRNS support price is $1.34 and resistance is $1.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNS stock will trade within this expected range on the day.